News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Cristian Massacesi: Very much enjoyed being part of the Endpoints panel at ASCO2024
Photo taken from Cristian Massacesi/LinkedIn
Jun 11, 2024, 11:49

Cristian Massacesi: Very much enjoyed being part of the Endpoints panel at ASCO2024

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer at AstraZeneca, posted on LinkedIn:

“Very much enjoyed being part of the Endpoints panel at ASCO2024. Alongside Julie Gralow, Timothy A. Yap and Kyle LaHucik, we reviewed the major scientific breakthroughs from this year’s conference and how these advances could potentially translate into improved outcomes for patients.

Themes from the discussion close to my heart included:

  • How the deeper convergence of science, data and technology can support smarter and faster decision-making in discovery and development.
  • How to further enhance precision medicine and better, targeted treatments in oncology, with great focus on how to improve and manage toxicities.
  • Exciting progress with new, disruptive modalities and the opportunities for combinations to offer even more transformational cancer regimens.
  • The growth in antibody drug conjugates and how they can be best sequenced across different disease settings for maximum impact.

Another excellent ASCO on many levels. There’s certainly never been a more exciting time to be working in oncology.”

Cristian Massacesi

Source: Cristian Massacesi/LinkedIn
.

Antibody drug conjugates ASCO2024 AstraZeneca cancer cancer regimen transformation combination therapies Cristian Massacesi data utilization disease sequencing disruptive modalities Endpoints panel OncoDaily Oncology oncology advancements oncology progress patient outcomes Precision Medicine science convergence scientific breakthroughs targeted treatments technology integration Toxicity management
Special Coverage
Insight
Nov 13, 2024, 07:41
Key Factors in Menstrual Recovery for Pre-menopausal Breast Cancer on Tamoxifen
Insight
Nov 13, 2024, 07:12
Luigi Lorini was awarded the 2024 Martin "Mac" Cheever Excellence in Clinical Trial Design Travel Award for Immunoprevention
Blog
Nov 12, 2024, 23:10
Hesham ElGhazaly: Empowering Women’s Health Through Solidarity
Blog
Nov 12, 2024, 23:07
Helen’s Journey with Breast Cancer - The Max Foundation
Blog
Nov 12, 2024, 22:58
Webinar on Lung Cancer Highlights from ESMO 2024 - SPCC
Blog
Nov 12, 2024, 22:56
Sanjay Juneja: The Challenge of Innovation in Cancer Treatment
Blog
Nov 12, 2024, 22:52
Session on cervical cancer screening programs and managing cervical pre-cancer in women living with HIV at IPVC 2024 - IARC
Blog
Nov 12, 2024, 22:50
Penilla Gunther: First time speaking at the POLITICO Europe Healthcare Summit
Blog
Nov 12, 2024, 22:46
Addressing AMR for Better Cancer Care During London Global Cancer Week - UICC
Blog
Nov 12, 2024, 22:43
Applications Open for 2025 CancerX Accelerator - CancerX Moonshot
Blog
Nov 12, 2024, 22:40
Wafik S. El-Deiry: Welcoming Dr. Dinara Ryspayeva to Brown University for Therapeutic Advances in Oncology
Celebrities
Nov 12, 2024, 19:50
Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More